• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Initial practice of left atrial appendage closure device in Japan; single-center experience
CONCLUSIONS: In this initial Japanese experience, LAAC therapy for high bleeding risk patients with NVAF seems feasible. Optimal antithrombotic regimens are warranted for better clinical outcomes.PMID:35094892 | DOI:10.1016/j.jjcc.2022.01.004
Source: Journal of Cardiology - January 31, 2022 Category: Cardiology Authors: Masato Fukunaga Akihiro Isotani Shinichi Shirai Naoto Murakami Miho Nakamura Takashi Morinaga Kenichi Ishizu Kazuki Kitano Tatsuhiro Kataoka Masaomi Hayashi Kenichi Hiroshima Kenji Ando Source Type: research

Role of Monotherapy with a P2Y12 Inhibitor for Secondary Prevention in Patients with Established Atherosclerosis
Curr Cardiol Rep. 2022 Jan 13. doi: 10.1007/s11886-021-01627-8. Online ahead of print.ABSTRACTPURPOSE OF REVIEW: The role of monotherapy with a P2Y12 inhibitor for secondary prevention of cardiovascular diseases has been assessed in several randomized trials. In this article, we summarize the evidence regarding P2Y12 monotherapy for secondary prevention in each one of the major vascular territories.RECENT FINDINGS: Available data including a large recent meta-analysis show no differences in terms of all-cause death, vascular death, stroke, and a minor difference of the risk of myocardial infarction with P2Y12 monotherapy a...
Source: Atherosclerosis - January 14, 2022 Category: Cardiology Authors: Juan J Rodriguez Luis E Baron Oscar C Munoz Jonathan J Diaz Source Type: research

Antithrombotic therapy with or without clopidogrel after transcatheter aortic valve replacement. A meta-analysis of randomized controlled trials
ConclusionsIn patients receiving TAVR, a therapeutic strategy of aspirin or OAC with clopidogrel significantly increases the risk of major bleeding without impact on mortality and ischemic outcomes compared to aspirin or OAC without clopidogrel. The performance of different antithrombotic regimens in terms of long-term clinical outcomes and bioprosthesis valve function requires further investigation.Graphic abstractForest plots from pairwise and network meta-analyses associated with an antithrombotic therapy with or without clopidogrel Risk ratio for all outcomes of interest calculated with the pairwise meta-analysis (left...
Source: Clinical Research in Cardiology - January 1, 2022 Category: Cardiology Source Type: research

Prevalence of VOYAGER PAD trial exclusion criteria in unselected patients undergoing lower limb revascularisation
CONCLUSIONS: In unselected patients undergoing revascularisation for peripheral arterial disease, the majority presents with characteristics that, at present, preclude prescription of rivaroxaban in addition to aspirin. This patient cohort represents a population with higher rates of comorbidities and more complex vascular interventions, but might also benefit from dual pathway inhibition strategy.PMID:34913631 | DOI:10.23736/S0392-9590.21.04816-1
Source: International Angiology - December 16, 2021 Category: Cardiology Authors: Maria A Moll Daniela Zwerger Kristina J Grassl Werner Westreicher Sabrina B Neururer Clemens Wi Moll Sabine H Wipper Josef Klocker Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20